Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

Optimi Health Corp. has successfully shipped its 5mg psilocybin capsules to Australia for patients with treatment-resistant depression, marking a significant milestone as this is their third commercial shipment since launching the treatment in September 2025. This development underscores the growing acceptance and regulatory approval of psychedelic therapies for mental health conditions. It highlights the potential of psilocybin in providing relief to those who have not responded to conventional treatments, making this export a pivotal step forward in mental health care innovation.